CLINICAL ROLE -
Video
Author(s):
Expert discusses the role of venetoclax in the treatment of AML and if achievement of MRD negativity can be used to predict long-term outcomes.
Distinct NK Cell Subset Predicts Ibrutinib Response and Immune Pathway Activation in CLL
The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma
Glofit-GemOx in R/R DLBCL: FDA Advisory Committee Reviews STARGLO Phase 3 Results for Transplant-Ineligible Patients
Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap
Real-World Study Shows Comparable Survival Outcomes With First-Line Ibrutinib in High-Risk and Non-High-Risk CLL/SLL
Anitocabtagene Autoleucel Yields Overall Response Rate of 97% in Patients With Multiple Myeloma